Infarcted hearts receiving Oct3/4 siRNA-treated CSCs did not demonstrate a formation of tumorigenesis 6 months after cell engraftment (data not shown), suggesting that Oct3/4 inhibition in c-kit+ CSCs does not increase the risk of developing teratomas. The gene discussed is POU5F1; the disease is teratoma.